
Routine versus As-Needed Bevacizumab with 12-Weekly Assessment Intervals for Neovascular Age-Related Macular Degeneration: 92-Week Results of the GMAN Trial
Keywords: AE; adverse event; BCVA; best-corrected visual acuity; CATT; Comparison of AMD Treatment Trials; CI; confidence interval; FFA; fluorescein angiography; GMAN; Greater Manchester Avastin for Neovascularisation; nAMD; neovascular age-related macular degenera